



Exchange Act. o

---

Item 7.01. Regulation FD Disclosure.

The information provided pursuant to this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item 7.01 shall instead be deemed “furnished.”

On January 18, 2018, CTI BioPharma Corp. (the “Company”) issued an Italian Press Release disclosing the expected effective date of the merger of the Company with and into its wholly-owned Delaware subsidiary named CTI Biopharma Corp. and the delisting from Borsa Italiana’s Main Market (MTA), subject to shareholder approval at the shareholders’ meeting. An English translation of the Italian Press Release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	<u>English Translation of Press Release of CTI BioPharma Corp., dated January 18, 2018.</u>

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: January 18, 2018 By: /s/ David H. Kirske  
David H. Kirske  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit No.	Description
<u>99.1</u>	<u>English Translation of Italian Press Release of CTI BioPharma Corp., dated January 18, 2018.</u>